Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study

Summary

In this exploratory trial, the potential anti-seizure activity of clioquinol in a small cohort of adolescents with drug-resistant epilepsy will be examined. Subjects will be exposed to clioquinol add-on for a period of maximum 8 weeks (2 weeks low dose, 6 weeks higher dose). The main hypothesis of the study is that 30% of the included subjects will be responders and that the median seizure frequency reduction will be at least 30%.

Timeline

Start

2022-03-01

Primary completion

2023-12-31

Completion

2023-12-31

Drugs

Indications